Peptide therapy TikTok claims: what the science actually supports

What did @taylorreidcoachin actually say?

The creator described a self-directed escalating dose protocol for 5-amino-1MQ, starting at 500 micrograms, moving to 750 micrograms, then up to 1 milligram. They described this as "micro dosing" and said they "listen to my body and feel it out" rather than following any fixed schedule. Cycles run four to eight weeks, followed by a four-week break before restarting.

To be clear: this is a personal account, not medical advice, and the creator frames it that way. They're not citing a protocol from a clinical trial. They're describing what they personally do. That context matters when evaluating it, because the absence of a cited evidence base is exactly the problem here, not a technicality.

Does the science back this up?

Barely, and not in the way the video implies. 5-amino-1MQ is a small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor, not a peptide in the classical sense. The science on it is early-stage and almost entirely preclinical.

The most relevant work comes from Neelakantan et al. (2019, Journal of Medicinal Chemistry), which showed NNMT inhibition in mouse models reduced fat mass and improved metabolic markers. That's promising. But mouse pharmacokinetics do not translate directly to human dosing, and there are no published Phase I or Phase II human clinical trials establishing safe or effective dose ranges for 5-amino-1MQ in people. The dose range the creator describes, 500 mcg to 1 mg, may be in a plausible ballpark based on anecdotal use in the biohacking community, but calling it "micro dosing" is not a clinically defined term here. It's borrowing language from psychedelic protocols and applying it loosely.

What did they get wrong (or right)?

The cycling approach, four to eight weeks on, four weeks off, is reasonable harm-reduction thinking for any compound with limited long-term human safety data. That part is defensible. If you're going to use something with no long-term human trials, building in breaks is not a bad instinct.

What's harder to defend is framing 5-amino-1MQ as a "peptide." It is not. It's a small-molecule inhibitor. This matters because peptide regulations, handling, and dosing intuitions don't automatically carry over. Categorizing it this way may give viewers false confidence that dosing intuition from, say, BPC-157 applies here. It doesn't.

The creator also says there "isn't really any direct, like, certain pathway" they follow. That's honest, but it's also the crux of the problem. There is no established human dosing pathway because the research simply hasn't been done yet. Admitting that would have been more useful than implying personal experience fills that gap.

What should you actually know?

5-amino-1MQ is not approved by the FDA for any therapeutic use. It is not a peptide. The existing evidence for NNMT inhibition as a metabolic strategy is genuinely interesting, with animal data from Neelakantan et al. (2019) and follow-up work from Hong et al. (2015, Biochemistry) showing metabolic reprogramming effects, but none of this establishes a human dose.

Anyone considering this compound should understand a few things. First, no published study has defined a minimum effective dose or a safety ceiling in humans. Second, "listening to your body" is not a substitute for pharmacokinetic data. Subjective tolerance is a poor proxy for liver burden, off-target effects, or long-term enzyme inhibition consequences. Third, if you are working with a prescribing clinician through a regulated telehealth platform, dose decisions should be driven by your individual lab work and medical history, not a TikTok escalation schedule.

The four-week washout the creator describes is also not validated. It may be reasonable. It may be too short or too long. Nobody currently knows, because the trials haven't been run.